Loading…

Abstract B73: Integration of a personalized molecular targeted therapy into the multimodal treatment of refractory early childhood sPNET

Background: Supratentorial primitive neuroectodermal tumors (sPNET) are highly-malignant and rare brain tumors that primarily affect young children. Despite multimodal treatment that includes surgery, radiotherapy and chemotherapy, less than half of affected patients will survive 5 years post-diagno...

Full description

Saved in:
Bibliographic Details
Published in:Cancer research (Chicago, Ill.) Ill.), 2014-10, Vol.74 (20_Supplement), p.B73-B73
Main Authors: Hartman, Lisa LR, Farah, Diba, Mulne, Arlynn F., Storrs, Bruce B., Wilson, Harry L., Bryson, Staci, Oaxaca, Derrick M., Kirken, Robert A., Ross, Jeremy A.
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Supratentorial primitive neuroectodermal tumors (sPNET) are highly-malignant and rare brain tumors that primarily affect young children. Despite multimodal treatment that includes surgery, radiotherapy and chemotherapy, less than half of affected patients will survive 5 years post-diagnosis. Moreover, neurocognitive impairment associated with current treatment protocols is a significant complication in survivors. Therefore, new molecular targeted therapies that are effective and less toxic are needed to further improve outcomes in sPNET patients. Tyrosine kinase inhibitors (TKI) have emerged as an important class of molecular targeted anti-cancer agents with demonstrated clinical efficacy and generally favorable toxicity profiles. Dasatinib, an orally-administered TKI that is FDA approved for Ph+ CML/ALL, has been reported in off-label use for cancers of the head and neck, breast, colon, prostate and lung. Dasatinib targets multiple tyrosine kinases that are involved in numerous cancers, including ABL, SRC family tyrosine kinases (SFKs), and receptor tyrosine kinases c-KIT and PDGFR. Notably, SFKs have been implicated in driving the development and progression of numerous solid tumors, including PNET and medulloblastoma. Methods: Here we report the successful use of dasatinib with informed consent in multimodal treatment of a 32 month old, ex-29 week twin B female patient. She was diagnosed with sPNET that demonstrated high tumor SFK-activity, had progressed on standard chemotherapy, and for whom irradiation was avoided due to the unwanted side effects of radiation on the developing brain. Multiplex kinase-activity profiling, and electron microscopy analysis was performed on pre- and post-dasatinib treatment tumor tissue after partial resections. Additionally, pre-and post-treatment MRI was done to quantitate the clinical response with dasatinib. Results: Ex vivo multiplex analysis revealed aberrant activation of SFKs SRC, LYN and FYN in the sPNET tumor, which was shown to be significantly reduced following dasatinib therapy. In addition, blockade of SFK activity with dasatinib correlated with greatly reduced activation of downstream proliferative transcription factors STAT1 and STAT3. Electron microscopy analysis of the tumor upon surgical resection revealed phenotypic changes with significant presence of autophagocytic vacuoles, indicative of cellular sequestration, and increased prominence of nuclear heterochromatin. Dasatinib therapy over a
ISSN:0008-5472
1538-7445
DOI:10.1158/1538-7445.PEDCAN-B73